Meta-iodobenzylguanidine (MIBG) is an analogue of noradrenalin which concentrates in adrenergic vesicles. Studies performed with an iodine-131 radiolabelled form (1311-MIBG) have shown that it can be used as an imaging agent for the adrenal medulla (Fischer et al., 1984) and its neoplasms (phaeochromocytoma and neuroblastoma) (Hoefnagel et al., 1987; Kimmig et al., 1984) . 1311-MIBG has also been shown to localise in paraganglioma, another tumour arising from the sympathetic nervous system (Pease & Polak, 1978) , and in medullary carcinoma of the thyroid (Shapiro et al., 1985) . These tumours show a common APUD (amine precursor uptake and decarboxylation) mechanism (Sisson et al., 1981) . Carcinoid tumours also possess a number of APUD properties, including in particular neurosecretory (dense core) granules and the ability to produce a variety of biogenic amines. Preliminary studies have suggested that carcinoid tumours may also take up '311-MIBG (Sisson et al., 1984; Smit et al., 1984) .
If carcinoid tumours were shown to take up this radiopharmaceutical with sufficient concentration then it might be possible to achieve therapeutic doses of 131I-MIBG, a technique successfully employed with malignant phaeochromocytoma (Sone et al., 1985) .
We describe a study to investigate further the uptake of 1311-MIBG for diagnostic imaging in II patients with confirmed metastatic carcinoid tumours.
Eleven patients known to have metastatic carcinoid tumours were studied. In 5 patients secondary deposits were histologically confirmed as carcinoid. The remaining 6 patients had metastatic tumours diagnosed by CT scanning or ultrasound and elevated urinary 5 hydroxyindoleacetic acid (5HIAA) levels, the original primary tumour had been diagnosed histologically. Ten of the II patients had abdominal CT scan or ultrasound to document metastases. An NMR scan was performed in one patient (10). Bone scans were only performed in patients with bone pain. Patient details are shown in Table I .
The patients received 0.3ml of Lugol's iodine 3 times a day for 3 days prior to and 3 days after administration of 131I-MIBG to prevent thyroid uptake of the radioiodine.
131I-MIBG (20-40mBq) was injected intravenously.
Imaging was performed at 24 and 48h following injection for all patients, and at 72h in 6 patients, using a Siemen's ZLC75 Gamma camera. A medium energy collimator was used with the peak set at 350KeV and a window of 15%. Images were acquired over 600 seconds. Planar anterior and posterior views of the chest and abdomen were taken with selective views of clinically involved areas. We found no correlation between the urinary 5HIAA levels and 1311-MIBG uptake in the tumours. One patient (6) had levels only modestly raised at 132 ,mol 24 h-I (N< 75,umol 24 h -1) but an unequivocally positive scintigram and marked symptoms while another patient with 5HIAA levels 5 times this level had a negative scintigram.
We also found no relationship between 'carcinoid symptomatology' and 131I-MIBG uptake. Patient 5 suffered florid carcinoid symptoms (with elevated urinary 5HIAA levels) but no uptake of the 1311-MIBG was seen.
We did not observe an increase in uptake of the 131I-MIBG after 48h and therefore scanning at 72h was discontinued. Compared with other studies we saw low levels of myocardial activity at 48h (none in 6/11 patients).
Our results confirm that 1311-MIBG is preferentially taken up by the majority of metastatic carcinoid tumours, with a 73% positive uptake in this study compared with 63% in Hoefnagel's series (Hoefnagel et al., 1987) . However, this incidence is lower than in malignant phaeochromocytoma where more than 90% of lesions take up 131I-MIBG (Wieland et al., 1981) . In keeping with other authors we found no correlation between urinary 5HIAA and 131I-MIBG uptake. However, we were unable to confirm the relationship between carcinoid symptomatology and 1311-MIBG uptake reported by Hoefnagel et al. (1987) .
We were unable to demonstrate preferential uptake of radiolabelled MIBG in particular sites. Although our only patient with bony metastases did not show any uptake of 1311-MIBG, Hoefnagel found that 2 of 3 patients with bone involvement showed abnormal uptake.
In 2 patients the uptake varied from lesion to lesion. The I 311-MIBG scintigram suggested a solitary hepatic metastasis, while the CT scan showed multiple lesions. It is possible that these appearances represent a mixture of func- The preferential uptake of 1311-MIBG by phaeochromocytomas has led to successful attempts at radiotherapeutic ablation using larger doses of this radiopharmaceutical (Sone et al., 1985) . A small number of patients with carcinoid have also been treated in this way and although some symptomatic improvements have been seen, no tumour regression has so far been reported (Hoefnagel et al., 1987) . Nevertheless the frequency of positive uptake suggests that the therapeutic potential merits further investigation.
